ARTICLE | Company News
FDA to discuss J&J's simeprevir
September 17, 2013 1:04 AM UTC
FDA's Antiviral Drugs Advisory Committee will meet on Oct. 24 to discuss an NDA from the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) for simeprevir to treat HCV genotype 1 ...